April 11, 2012
With the successful launch in Sweden, Uniferon is now available
in all Nordic countries.
Denmark, Sweden, Norway and Finland are recognized for having
some of the most demanding pig producers in the world, and the
presence of Uniferon on these strategically important markets marks
a significant step in our global endeavours.
The availability of Uniferon also ensures a short distance
between Pharmacosmos and our customers, and it enables us to
produce and deliver the best quality across borders.
International Sales Manager Christian von der Recke is very
pleased with this recent progress: "Our presence in all Nordic
countries is a testament to not least our partners' diligent work
in the region, and it bodes extremely well for the future
development of these important markets. And with one entrance to
the entire region we can maintain and ensure a continued delivery
of high quality iron to the pig farmers."
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.